Bactrim Dosing Based on eGFR
For patients with eGFR ≥30 mL/min, use standard Bactrim dosing without adjustment; reduce the dose by 50% when eGFR is 15-30 mL/min, and avoid use entirely when eGFR is <15 mL/min unless treating life-threatening Pneumocystis jirovecii pneumonia. 1
Standard Dosing for Normal Renal Function (eGFR >30 mL/min)
Urinary tract infections and most bacterial infections: 1 double-strength (DS) tablet (800 mg sulfamethoxazole/160 mg trimethoprim) every 12 hours for 10-14 days 1
Pneumocystis jirovecii pneumonia (PCP) treatment: 75-100 mg/kg/day sulfamethoxazole with 15-20 mg/kg/day trimethoprim, divided every 6 hours for 14-21 days (typically 2 DS tablets every 6 hours for a 70 kg adult) 1
PCP prophylaxis: 1 DS tablet daily or 1 single-strength tablet daily 1
Dose Adjustment for Moderate Renal Impairment (eGFR 15-30 mL/min)
Reduce the standard dose by 50% for all indications when creatinine clearance falls between 15-30 mL/min 1
For UTI treatment, this translates to 1 single-strength tablet every 12 hours or 1 DS tablet every 24 hours 2
Recent pharmacokinetic modeling confirms that a 33% dose reduction is appropriate at eGFR 30 mL/min and a 33.3% reduction at eGFR 10 mL/min to maintain equivalent drug exposure 3
Severe Renal Impairment (eGFR <15 mL/min)
Use is not recommended when creatinine clearance is below 15 mL/min due to accumulation of both active drug and toxic metabolites 1
The N-acetyl sulfamethoxazole metabolite accumulates significantly in severe renal impairment and may contribute to toxicity 3
Exception for life-threatening PCP: In dialysis-dependent patients with PCP, some clinicians use 3-5 mg/kg trimethoprim every 24 hours with close monitoring, though this is not FDA-approved 2, 4
Critical Dosing Considerations
Trimethoprim falsely elevates serum creatinine by 10-40% within 2-4 days by blocking tubular creatinine secretion without actually reducing GFR 5, 6. This means:
- A rising creatinine on Bactrim does not necessarily indicate worsening kidney function 5
- Use the baseline eGFR measured before starting Bactrim for dose adjustment decisions, not values obtained during treatment 5
- If creatinine rises >30% or BUN increases significantly, consider true nephrotoxicity from the sulfamethoxazole component and discontinue the drug 6
Monitoring Requirements in Renal Impairment
Check electrolytes within 3-5 days of starting therapy, as trimethoprim doses >160 mg/day significantly increase risk of hyperkalemia (29.4% incidence) and hyponatremia (64.7% incidence) through distal tubular effects 6
For PCP treatment in renal impairment, therapeutic drug monitoring of trimethoprim levels (target peak 5-10 mcg/mL) can guide dosing, especially when eGFR <30 mL/min 4
The dosing interval in severe renal failure should be increased to 12 times the serum creatinine level in mg/dL (maximum 48-hour interval) 4
Dialysis Patients
Hemodialysis: Bactrim is poorly dialyzed (peritoneal dialysance only 5.1 mL/min for trimethoprim and 1.2 mL/min for sulfamethoxazole), so supplemental dosing after dialysis is generally not required 7
Peritoneal dialysis: Half-life extends to 23.7 hours for trimethoprim and 18.1 hours for sulfamethoxazole; use 50% of standard dose or consider alternative agents 7
For peritonitis in peritoneal dialysis patients, intraperitoneal administration achieves immediate high local concentrations with therapeutic systemic levels within 6-12 hours 7
Common Pitfalls to Avoid
Do not use creatinine-based eGFR equations during active Bactrim therapy to assess kidney function, as trimethoprim artificially raises creatinine by 0.4-0.5 mg/dL on average 5
Avoid combining Bactrim with other potassium-sparing agents (ACE inhibitors, ARBs, spironolactone) in patients with eGFR <60 mL/min without close potassium monitoring 6
The sulfamethoxazole component, not trimethoprim, causes true nephrotoxicity at high doses or with inadequate dose adjustment 5
In elderly patients, age-related GFR decline may not be reflected in serum creatinine due to reduced muscle mass; calculate actual creatinine clearance using Cockcroft-Gault or measure cystatin C-based eGFR 2